Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

25 janvier 2013 mis à jour par: Centocor, Inc.

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Aperçu de l'étude

Statut

Retiré

Les conditions

Intervention / Traitement

Description détaillée

This is a research study with an experimental drug called siltuximab (also known as CNTO 328). Siltuximab is being developed to see if it may be useful in treating multiple myeloma, including multiple myeloma that has returned after (relapsed) or did not respond (refractory) to previous treatment. Multiple myeloma is a type of cancer that affects the blood and bone marrow. The cancer cells in the bone marrow can cause the normal bone marrow cells to breakdown. This can result in low levels of red blood cells (which may make the patient feel tired or fatigued), low levels of white blood cells (which may increase the patient's chances of infections) or low levels of platelets (which may increase risk of bleeding). The cancer cells can cause damage to the normal bone. This can cause bone pain, bone fractures, and can increase the level of calcium in the blood. The cancer cells also make proteins (called M-proteins), which can result in damage to other organs, especially the kidneys. Siltuximab is a chimeric (part mouse and part human) antibody (immunoglobulin that is important for fighting infection). Siltuximab blocks another small protein called Interleukin 6 (IL-6). The body makes IL-6 naturally, and at normal levels it is important for the inflammatory response. But high levels of IL-6 can help cancer cells grow and interfere with chemotherapy drugs killing cancer cells. Cancer-related sicknesses such as weight loss, bone weakening, and depression have been linked to high levels of IL-6. This study tests the effectiveness and safety of siltuximab when it is taken together with Velcade and dexamethasone. There are two treatment groups, Arm A and Arm B. To try to make sure the groups are similar, patients will be put into Arm A or Arm B, randomly (by chance), like flipping a coin. Patients in Arm A will receive siltuximab plus Velcade and dexamethasone. Patients in Arm B will receive placebo plus Velcade and dexamethasone. About 500 patients will participate in the study. Velcade, also known as bortezomib, is injected directly into the vein all at once. This is called an intravenous (IV) push. Siltuximab or placebo is given as a 1 hour IV infusion through a small tube that goes directly into the vein. Dexamethasone is given orally. The treatment period is divided into cycles lasting about 21 days which will last until the patient's multiple myeloma gets worse, side effects that are not acceptable happen or when the patient decides to withdraw consent for treatment, whichever occurs first. Siltuximab 11mg/kg or placebo will be given on Day 1 of every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles 1-8, and on Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the day of and the day after each Velcade dose. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g. blood pressure), and checking the occurrence and severity of adverse events. Disease assessments will also be performed and include obtaining and evaluating blood and 24 hour urine samples, bone marrow aspirate and/or biopsy samples and clinical and radiologic evaluations. After treatment, patients will enter the follow-up period, which includes visits up to 12 weeks after the last dose and checks every three months until death or the end of the study. Patients who stop treatment before their multiple myeloma gets worse will have disease assessments until their disease gets worse, they start a new multiple myeloma treatment, they decide to withdraw consent for study participation or the end of the study, whichever happens first. Siltuximab or placebo plus Velcade and dexamethasone will be given in 21-day treatment cycles until worsening of disease (progression), unacceptable toxicity or withdrawal of consent for treatment, whichever comes first. Siltuximab 11 mg/kg or placebo will be given on Day 1 of every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles 1-8, and on Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the day of and the day after each Velcade dose.

Type d'étude

Interventionnel

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Australie
      • Adelaide, Australie
      • Camperdown, Australie
      • Heidelberg, Australie
      • Parkville, Australie
      • Prahran, Australie
  • Belgique
      • Edegem, Belgique
      • Liège, Belgique
      • Turnhout, Belgique
      • Yvoir, Belgique
  • Bulgarie
      • Plovdiv N/A, Bulgarie
      • Sofia, Bulgarie
      • Varna, Bulgarie
  • Canada
      • Toronto, Canada
  • Corée, République de
      • Hwasun Gun, Corée, République de
      • Seoul, Corée, République de
  • Inde
      • Gandhinagar Guiarat, Inde
  • Nouvelle-Zélande
      • Christchurch, Nouvelle-Zélande
      • Grafton, Nouvelle-Zélande
      • Nz 9 Takapuna Auckland, Nouvelle-Zélande
      • Palmerston North, Nouvelle-Zélande
  • Pays-Bas
      • Apeldoorn, Pays-Bas
      • Deventer, Pays-Bas
      • Zwolle, Pays-Bas
  • Pologne
      • Brzozow, Pologne
      • Gdansk, Pologne
      • Lodz, Pologne
      • Opole, Pologne
      • Wroclaw, Pologne
  • Royaume-Uni
      • Nottingham, Royaume-Uni
  • République tchèque
      • Hradec Kralove, République tchèque
      • Liberec, République tchèque
      • Praha, République tchèque
      • Praha 2, République tchèque
  • Turquie
      • Ankara, Turquie
      • Bursa, Turquie
      • Edirne, Turquie
  • Ukraine
      • Cherkassy, Ukraine
      • Dnepropetrovsk, Ukraine
      • Kharkov, Ukraine
      • Khmelnitskiy, Ukraine
      • Kiev, Ukraine
      • Odessa, Ukraine
      • Simferopol, Ukraine
      • Vinnitsa, Ukraine
  • États-Unis
    • Iowa
      • Iowa City, Iowa, États-Unis
    • Massachusetts
      • Boston, Massachusetts, États-Unis
    • Ohio
      • Toledo, Ohio, États-Unis
    • Pennsylvania
      • Willow Grove, Pennsylvania, États-Unis
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma requiring treatment
  • Measurable secretory disease, defined as either serum M-protein >=1 g/dL or urine M-protein (light chain) >=¿200 mg/24 hours
  • Must have received 1 to 3 lines of prior treatment for multiple myeloma
  • Must have achieved a response (Minimal Response or better) to at least 1 prior line of treatment
  • Must have progressed on or been refractory (defined as < Minimal Response or disease progression within 60 days of last dose) to the most recent line of treatment
  • Must not be refractory to any previous line of treatment that included a proteasome inhibitor
  • Qualifying hematology and chemistry laboratory results.

Exclusion Criteria:

  • Diagnosis of primary amyloidosis, plasma cell leukemia, or other conditions in which a paraprotein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy
  • Allogeneic bone marrow transplantation within 28 days
  • Bone marrow transplant planned within 12 months after study start
  • Chemotherapy or radiation therapy within 21 days
  • Clinically significant infection, including known HIV or hepatitis C infection, or known hepatitis B surface antigen positivity
  • Major surgery within 21 days before or planned during the study
  • Subjects who the investigator believes would not tolerate starting doses of VELCADE or dexamethasone
  • Significant cardiac disease or myocardial infarction within 6 months
  • Vaccination with live attenuated vaccines within 4 weeks
  • Prior exposure to agents targeting IL-6 or the IL-6 receptor
  • Received any investigational agent within 30 days¿

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: 001
Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
Biologique: Siltuximab, Velcade and dexamethasone
Given in 21-day treatment cycles
Autre: 002
Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
Médicament: Placebo, Velcade and dexamethasone
Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Progression-free survival (PFS)
Délai: Event driven, i.e. every 3-4 weeks until progression, death, or end of study (5 years after first patient is dosed)
Event driven, i.e. every 3-4 weeks until progression, death, or end of study (5 years after first patient is dosed)

Mesures de résultats secondaires

Mesure des résultats
Délai
Overall survival
Délai: Every 3 months until death or end of study (5 years after 1st patient is dosed)
Every 3 months until death or end of study (5 years after 1st patient is dosed)
Overall response rate
Délai: Every 3 weeks until disease progression or end of study (5 years after 1st patient is dosed)
Every 3 weeks until disease progression or end of study (5 years after 1st patient is dosed)
Siltuximab pharmacokinetic evaluations (Cmin, Cmax) to provide information on the pharmacokinetic profile of siltuximab
Délai: Day 1 of Cycles 1, 2, 3, 5, 7, 11, 15, and 19 and during the follow-up period (12 weeks after last dose)
Day 1 of Cycles 1, 2, 3, 5, 7, 11, 15, and 19 and during the follow-up period (12 weeks after last dose)
Dexamethasone pharmacokinetic evaluations (Cmin, AUC[t1-t2]) from approx. 30 patients from each treatment arm to provide information on the pharmacokinetic profile of dexamethasone
Délai: Pre-dose on Day 1 of Cycles 1, 2 and 3; at Cycle 3 measured 1, 2, 4, 6 and 24 hours after dose
Pre-dose on Day 1 of Cycles 1, 2 and 3; at Cycle 3 measured 1, 2, 4, 6 and 24 hours after dose
Number of adverse events as a measure of safety and tolerability
Délai: Routinely until 30 days after last dose at a minimum, or until end of study
Routinely until 30 days after last dose at a minimum, or until end of study

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Centocor, Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2011

Achèvement primaire (Anticipé)

1 avril 2014

Achèvement de l'étude (Anticipé)

1 décembre 2014

Dates d'inscription aux études

Première soumission

23 décembre 2010

Première soumission répondant aux critères de contrôle qualité

23 décembre 2010

Première publication (Estimation)

24 décembre 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

28 janvier 2013

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 janvier 2013

Dernière vérification

1 janvier 2013

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • CR017743
  • CNTO328MMY3001 (Autre identifiant: Centocor, Inc.)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner